144 related articles for article (PubMed ID: 8127053)
1. Hereditary tyrosinaemia type I: a long-term study of the relationship between the urinary excretions of succinylacetone and delta-aminolevulinic acid.
Schierbeek H; Beukeveld GJ; van Faassen H; van Spronsen FJ; Bijsterveld K; Venekamp-Hoolsema EE; Wolthers BG; Smit GP
J Inherit Metab Dis; 1993; 16(6):1034-40. PubMed ID: 8127053
[TBL] [Abstract][Full Text] [Related]
2. Urinary succinylacetone presence and delta-aminolaevulinic acid excretion in patients with type I tyrosinaemia during treatment.
Pronicka E; Mielniczuk Z; Rowińska E; Ksiazyk J; Szczygielska-Kozak M; Wieczorek E; Kulczycka H
Mater Med Pol; 1991; 23(2):136-8. PubMed ID: 1842600
[TBL] [Abstract][Full Text] [Related]
3. Urinary excretion of succinylacetone and delta-aminolevulinic acid in patients with hereditary tyrosinemia.
Christensen E; Jacobsen BB; Gregersen N; Hjeds H; Pedersen JB; Brandt NJ; Baekmark UB
Clin Chim Acta; 1981 Nov; 116(3):331-41. PubMed ID: 7296896
[TBL] [Abstract][Full Text] [Related]
4. Contribution of extrahepatic tissues to biochemical abnormalities in hereditary tyrosinemia type I: study of three patients after liver transplantation.
Tuchman M; Freese DK; Sharp HL; Ramnaraine ML; Ascher N; Bloomer JR
J Pediatr; 1987 Mar; 110(3):399-403. PubMed ID: 3546650
[TBL] [Abstract][Full Text] [Related]
5. Liver transplantation in nine Spanish patients with tyrosinaemia type I.
Pérez-Cerdá C; Merinero B; Sanz P; Castro M; Gangoiti J; García MJ; Díaz M; Medina E; Ugarte M
J Inherit Metab Dis; 1995; 18(2):119-22. PubMed ID: 7564224
[No Abstract] [Full Text] [Related]
6. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase.
Lindstedt S; Holme E; Lock EA; Hjalmarson O; Strandvik B
Lancet; 1992 Oct; 340(8823):813-7. PubMed ID: 1383656
[TBL] [Abstract][Full Text] [Related]
7. Tyrosinaemia type Ia without excess of urinary succinylacetone.
Biasucci G; Giuffré B; La Grutta S; Riva E
J Inherit Metab Dis; 1993; 16(6):1056-7. PubMed ID: 8127063
[No Abstract] [Full Text] [Related]
8. Succinylacetone and delta-aminolevulinic acid dehydratase in hereditary tyrosinemia: immunochemical study of the enzyme.
Sassa S; Fujita H; Kappas A
Pediatrics; 1990 Jul; 86(1):84-6. PubMed ID: 2359685
[TBL] [Abstract][Full Text] [Related]
9. Hereditary tyrosinemia and the heme biosynthetic pathway. Profound inhibition of delta-aminolevulinic acid dehydratase activity by succinylacetone.
Sassa S; Kappas A
J Clin Invest; 1983 Mar; 71(3):625-34. PubMed ID: 6826727
[TBL] [Abstract][Full Text] [Related]
10. Hereditary tyrosinemia. Formation of succinylacetone-amino acid adducts.
Manabe S; Sassa S; Kappas A
J Exp Med; 1985 Sep; 162(3):1060-74. PubMed ID: 3928801
[TBL] [Abstract][Full Text] [Related]
11. Persistent succinylacetone excretion after liver transplantation in a patient with hereditary tyrosinaemia type I.
Tuchman M; Freese DK; Sharp HL; Whitley CB; Ramnaraine ML; Ulstrom RA; Najarian JS; Ascher N; Buist NR; Terry AB
J Inherit Metab Dis; 1985; 8(1):21-4. PubMed ID: 2581063
[TBL] [Abstract][Full Text] [Related]
12. Lack of hemodynamic effects after extended heme synthesis inhibition by succinylacetone in rats.
Bourque SL; Benjamin CD; Adams MA; Nakatsu K
J Pharmacol Exp Ther; 2010 Apr; 333(1):290-6. PubMed ID: 20071481
[TBL] [Abstract][Full Text] [Related]
13. Succinylacetone inhibits delta-aminolevulinate dehydratase and potentiates the drug and steroid induction of delta-aminolevulinate synthase in liver.
Sassa S; Kappas A
Trans Assoc Am Physicians; 1982; 95():42-52. PubMed ID: 7182986
[TBL] [Abstract][Full Text] [Related]
14. Dietary treatment eliminates succinylacetone from the urine of a patient with tyrosinaemia type 1.
Bain MD; Purkiss P; Jones M; Bingham P; Stacey TE; Chalmers RA
Eur J Pediatr; 1990 Jun; 149(9):637-9. PubMed ID: 2373116
[TBL] [Abstract][Full Text] [Related]
15. On rat renal aminolevulinate transport and metabolism in experimental Fanconi syndrome.
Roth KS; Carter BE; Moses LC; Spencer PD
Biochem Med Metab Biol; 1990 Dec; 44(3):238-46. PubMed ID: 2288767
[TBL] [Abstract][Full Text] [Related]
16. Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up.
Pierik LJ; van Spronsen FJ; Bijleveld CM; van Dael CM
J Inherit Metab Dis; 2005; 28(6):871-6. PubMed ID: 16435179
[TBL] [Abstract][Full Text] [Related]
17. Plasma succinylacetone is persistently raised after liver transplantation in tyrosinaemia type 1.
Bartlett DC; Preece MA; Holme E; Lloyd C; Newsome PN; McKiernan PJ
J Inherit Metab Dis; 2013 Jan; 36(1):15-20. PubMed ID: 22456946
[TBL] [Abstract][Full Text] [Related]
18. On the renal tubular damage in hereditary tyrosinemia and on the formation of succinylacetoacetate and succinylacetone.
Fällström SP; Lindblad B; Steen G
Acta Paediatr Scand; 1981; 70(3):315-20. PubMed ID: 7246125
[TBL] [Abstract][Full Text] [Related]
19. Identification of 4,6-dioxoheptanoic acid (succinylacetone), 3,5-dioxooctanedioic acid (succinylacetoacetate) and 4-Oxo-6-hydroxyheptanoic acid in the urine from patients with hereditary tyrosinemia.
Lindblad B; Steen G
Biomed Mass Spectrom; 1982 Oct; 9(10):419-24. PubMed ID: 7171740
[TBL] [Abstract][Full Text] [Related]
20. Clinical utilization of dried blood spot nitisinone (NTBC) and succinylacetone (SA) concentrations in hereditary tyrosinaemia type 1 - A UK centre experience.
Yeo M; Turner C; Dalton NR; Rahman Y; Vara R
Ann Clin Biochem; 2020 Nov; 57(6):412-419. PubMed ID: 32936663
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
